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Abstract
Dendritic cells (DCs) are the most potent antigen-presenting cells (APCs). Immature DCs (iDCs) are situated in the periphery
where they capture pathogen. Subsequently, they migrate as mature DCs (mDCs) to draining lymph nodes to activate T
cells. CCR7 and CCL21 contribute to the migratory capacity of the DC, but it is not completely understood what molecular
requirements are involved. Here we demonstrate that monocyte-derived DCs dramatically change ST8Sia IV expression
during maturation, leading to the generation of polysialic acid (polySia). PolySia expression is highly upregulated after 2
days Toll-like receptor-4 (TLR4) triggering. Surprisingly, only immunogenic and not tolerogenic mDCs upregulated polySia
expression. Furthermore, we show that polySia expression on DCs is required for CCL21-directed migration, whereby
polySia directly captures CCL21. Corresponding to polySia, the expression level of CCR7 is maximal two days after TLR4
triggering. In contrast, although TLR agonists other than LPS induce upregulation of CCR7, they achieve only a moderate
polySia expression. In situ we could detect polySia-expressing APCs in the T cell zone of the lymph node and in the deep
dermis. Together our results indicate that prolonged TLR4 engagement is required for the generation of polySia-expressing
DCs that facilitate CCL21 capture and subsequent CCL21-directed migration.
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Introduction
The transition of immature DCs (iDCs) to mature DCs (mDCs)
is well known to endow dendritic cells (DCs) with the capacity to
couple innate to adaptive immune responses. Resting iDCs reside
in the periphery, where they sense for pathogen by TLRs [1].
Upon pathogen recognition, a signaling cascade initiates the DC
maturation process, characterized by the upregulation of MHC
class II and co-stimulatory molecules. In order to initiate the
adaptive immune response, DCs travel through the lymphatics to
the draining lymph node. In the lymph node, they arrive as fully
matured DCs, able to promote the activation of naı¨ve T cells
through antigen presentation [2]. Therefore, the phenotypic and
functional changes associated with maturation are of critical
importance for a proper immune response.
Little is known about posttranslational protein modifications
that could contribute to the functional switch of iDCs to mDCs.
Several processes, such as T cell activation and differentiation
[3;4] as well as DC maturation [5;6] have been reported to be
accompanied by programmed remodeling of their cell surface
glycosylation. Glycosylation is a highly regulated process that takes
place in the Golgi apparatus by the step-wise addition of
carbohydrates by glycosyltransferases to maturing glycoproteins
and glycolipids [7]. Sialyltransferases comprise a large family of
glycosyltransferases that are responsible for the capping of glycans
with terminal sialic acids. DC maturation results in dramatic
changes in the gene expression profile of sialyltransferases, and
amongst them, ST8Sia IV appears to show the largest differences
[5]. ST8Sia IV is an a-N-acetylneuraminate a2,8-sialyltransferase
that catalyzes the transfer of sialic acid to a sialylated glycan to
generate polysialic acid (polySia) [8].
PolySia is a linear homopolymer of a2,8-linked sialic acids,
ranging up to 300 residues [9;10]. Although polySia expression
was originally thought to be exclusive expressed on NCAM on
neuronal cells, it has recently been found on several other
glycoproteins, such as the a-subunit of the voltage-sensitive sodium
channel in the brain [11], CD36 in human milk [12] and
neuropilin-2 on DCs [13]. Polysialylation of neuropilin-2 was
shown to negatively regulate the activity and T cell proliferative
capacity of DCs [13].
Migration of DCs from the periphery to the lymph node is
regulated by the expression of CCL21 in the secondary lymphoid
organs and its receptor CCR7expressed by mDCs [14]. Recently,
the sialomucin PSGL-1 has been described to interact with
CCL21 to facilitate the homing of T cells [15]. Although the
molecular mechanism by which PSGL-1 captures CCL21 and
contributes to chemotaxis is still unclear, it was suggested that the
negative charge contributed by the sulfate groups on PSGL-1 may
play a role, in analogy with the capacity of highly sulfated
glycosaminoglycans to capture CCL21 [16]. Based on these
findings we hypothesized that the upregulated expression of the
highly negatively charged polySia induced during maturation
could play a role in chemokine capture in order to facilitate DC
migration to the lymph node.
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In this study we have investigated the kinetics of polySia
expression during DC maturation and on several DC subsets. We
demonstrate that polySia on O-linked glycans on monocyte-
derived DCs is required for CCL21-directed migration through
binding of CCL21 to sialic acids on the DC surface. Additionally,
polySia expressing APCs were found in human tissue sections of
skin and lymph node.
Results/Discussion
DCs matured for 2 days with LPS express high levels of
polySia on O-glycans
DC maturation is associated with a functional change from
antigen capture towards migration to the lymph node and activation
of T cells. We recently observed that maturation also results in a
dramatic reprogramming of the glycosylation machinery, especially
with regard to sialylation [5]. DC maturation after triggering of
TLR4 with LPS resulted in the upregulation of a2,3- and a2,
8-linked sialyltransferase transcripts, whereas ST6Gal I transcripts,
encoding for an a2,6-sialyltransferase, were down regulated, as
measured by quantitative RT-PCR (Figure 1A). Interestingly,
ST8Sia IV transcripts levels were much higher than the remaining
sialyltransferase transcripts. ST8Sia IV is required for the
biosynthesis of the unusual glycan structure polySia [8,17]. In
contrast to monocytes, macrophages and iDC, the high expression
levels of ST8Sia IV transcripts appeared to be exclusive for mDC
(Figure 1B). In order to determine the kinetics of ST8Sia IV
upregulation during LPS-induced DC maturation, quantitative
RT-PCR analysis of ST8Sia IV mRNA was performed at different
time points after LPS treatment. Already 1 day after LPS treatment
ST8Sia IV transcripts were upregulated, which are further
enhanced on day 2, whereas the strongest upregulation was
observed 3 days after LPS treatment (Figure 1C). In contrast to
ST8Sia IV mRNA expression, no polySia expression was found on
the cell membrane of iDC and mDC matured for 1 day with LPS.
Cleary polySia levels were enhanced on DCmatured with LPS for 2
days as detected by staining with the specific antibody 735 [18]
(Figure 1D), indicating that at least one day is necessary for the
appropriate glycoprotein turnover and to allow newly synthesized
polySia containing glycoproteins to reach the extracellular mem-
brane. Since the viability of in vitro DC might be compromised after
a prolonged exposure to LPS, we have chosen to investigate the
effects of high levels of polySia on DC only after 2 days of LPS
exposure.
PolySia is commonly found on N-linked core structures attached
to NCAM on neuronal cells [9], but it has also been described to be
attached to O-linked glycans on CD36 [12]. To determine whether
polySia on mDCs is attached to O- or N-linked glycans, we used the
glycosylation inhibitors kifunensine and benzyl-a-GalNAc. The
Golgi mannosidase-inhibitor kifunensine [19] inhibits the matura-
tion of N-glycans rendering structures consisting of high-mannose.
Figure 1. DCs matured for 2 days with LPS express high levels
of O-linked polysialic acid. (A) mRNA levels of sialyltransferase
genes of iDCs or mDCs triggered for 1 day with LPS were determined by
quantitative RT-PCR. Averages of 6 donors are depicted. (B) Expression
levels of ST8Sia IV in myeloid cells as measured by quantitative RT-PCR
(N= 3). (C) Time course of ST8Sia IV expression after LPS triggering, as
analyzed by quantitative RT-PCR. One representative donor is shown.
(D) Expression levels of polySia by iDCs (dotted line) and DCs matured
for 2 days with LPS (bold line) or 1 day with LPS (thin line), as measured
by flow cytometry with moAb 735. Results are representative of 5
independent experiments. (E) Flow cytometric analysis of the glycosyl-
ation of mDCs treated with kifunensine to block N-glycan synthesis, or
with benzyl-a-GalNAc to block O-glycan synthesis using the lectins Con-
A (high-mannose structures) or HPA (Tn antigen). Depicted are the
relative fluorescence values of kifunensine or benzyl-a-GalNAc treated
cells compared to untreated cells. Relative fold increase in expression of
polySia after maturation (MFI mDC/MFI iDC) was analysed with mAb
735 (polySia). One representative donor is shown. (F, G) 50% of PolySia
expressed by mDCs is removed with neuraminidase and Endo-
neuraminidase treatment as analyzed by flow cytometry with moAb
735. One out of 3 independent experiments is shown.
doi:10.1371/journal.pone.0006987.g001
PolySia Regulates DC Migration
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O-glycan synthesis was blocked by treating the cells with benzyl-a-
GalNAc [20], an analogue of GalNAc that can not be used as
substrate by subsequent glycosyltransferases. Efficiency of inter-
ference with glycosylation was confirmed using the high-mannose-
specific lectin Con A and the GalNAc-specific lectin HPA. Highly
increased polySia expression levels were observed on kifunensine
(N-linked glycosylation) treated mDCs, while benzyl-a-GalNAc
(O-linked glycosylation) efficiently blocked the maturation-
induced polySia upregulation (Figure 1E). The apparently
contradictory increase in polySia expression induced by kifunen-
sine could be explained by a better availability of substrates for
O-linked glycan synthesis upon N-glycan biosynthesis blockade.
Together, these data indicate that polySia on mDC is O-linked to
glycoproteins. Treatment of mDCs with neuraminidase (NA),
removing a2,3-, a 2,6-, and a2,8-linked sialic acid, or Endo-
neuraminidase (Endo-N) specific for polySia, resulted in 50%
lower polySia expression, demonstrating the specificity of the
moAb 735 (Figure 1F and 1G).
CCL21 binding to sialic acids is required for CCL21-
directed migration of mDCs
It has been reported that some cytokines have carbohydrate-
binding properties. These cytokine-glycan interactions often
involve sialic acids, as demonstrated by the binding of IL-1a to
disialylated di-antennary N-glycans and IL-7 to a mucin rich in
sialyl-Tn antigen [21]. The chemokine CCL21 shows binding to
glycosaminoglycans [22] and recently it has been demonstrated
that CCL21 binds the glycoprotein PSGL-1 on T cells to facilitate
the migration of T cells to secondary lymphoid organs [15]. In
order to investigate if CCL21 directly binds to sialic acids and in
particular to polySia, we analysed CCL21 binding to sialylated
glycan-conjugated polyacrylamide probes (a2,8-di-, tri-, and a2,
8-polysialylated). As a control, polyacrylamide probes carrying the
neutral monosaccharide galactose were used. CCL21 did not bind
galactose, whereas the binding of CCL21 to sialic acid was clearly
present and positively correlated to the amount of sialic acids
present on the glycan structure (Figure 2A). The binding of
CCL21 to coated a2,6-linked sialic acid or a2,8-linked polySia
could be inhibited by the addition of soluble a2,8-linked polySia,
whereas the addition of soluble galactose did not affect CCL21
binding to sialic acids (Figure 2B).
Since DC migration is directed by CCL21 binding to CCR7 on
DCs and we observed direct binding of CCL21 to sialic acids, we
hypothesized that polySia on mDCs might promote DC migration
towards CCL21. To investigate this, the spontaneous and the
CCL21 directed migratory response of DCs with or without
polySia expression was measured in a transwell chemotaxis assay.
The migration of mDCs triggered for 1 day with LPS, (expressing
low polySia levels) were compared to the migration of mDCs
treated for 2 days with LPS (expressing high polySia levels). The
migratory response of mDCs treated for 2 days with LPS was
clearly higher than that of the mDCs with low polySia content
(Figure 2C). To demonstrate polySia requirement for CCL21-
induced DC migration, mDCs triggered for 2 days with LPS were
treated with NA or Endo-N to remove sialic acids. The reduction
in CCL21-induced migration (Figure 2D) paralleled the reduction
in polySia expresssion achieved by these treatments (Figure 1F),
demonstrating the involvement of these structures in the capture of
CCL21 to facilitate migration. To exclude that NA or Endo-N
treatment interferes with CCR7 function, we added soluble
galactose or polySia to CCL21-supplemented medium. The
migration of mDC triggered for 2 days with LPS to CCL21-
supplemented medium was inhibited with soluble polySia
compared to the addition of soluble galactose (Figure 2E). In
Figure 2. CCL21 binding to sialic acid is required for CCL21-
directed migration of DCs. (A) CCL21 binding to coated PAA-
conjugated glycans was analyzed by anti-CCL21 antibody and
peroxidated goat anti-mouse antibody binding. As a control, CCL21
was substituted by PBS (grey bar) or a murine IgG1 isotype control
(white bar) (N= 4). (B) Binding of CCL21 pre-incubated with PBS (black
bar), PAA-conjugated polySia (grey bar) or PAA-conjugated galactose
(white bar) to coated PAA-conjugated a2,6-linked sialic acid or a2,8-
linked polySia. CCL21 binding was analyzed by anti-CCL21 antibody and
peroxidated goat anti-mouse (N= 2). (C) DC migration to CCL21 was
measured in a transwell assay. Depicted are the numbers of migrated
DCs matured for 1 day with LPS (not expressing polySia) or for 2 days
with LPS (expressing polySia) to medium (white bar) or medium
supplemented with CCL21 (black bar) (N = 4). (D) Migration of mDCs
(2 days LPS) treated with NA or Endo-N to medium (white bar) or
medium supplemented with CCL21 (black bar) (N= 4). (E) Migration of
mDCs (2 days LPS) to CCL21 in the presence of soluble galactose or
a2,8-linked polySia (N= 4). Depicted is the relative migration of mDCs
towards CCL21 compared to medium controls.
doi:10.1371/journal.pone.0006987.g002
PolySia Regulates DC Migration
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conclusion, we demonstrate that CCL21 directly binds to sialic
acids, probably facilitated by the negative charge of sialic acids.
PolySia expression on mDCs could thus create a negatively
charged capture mechanism to efficiently promote CCL21-
directed migration.
PolySia is primarily upregulated on DCs matured for 2
days with TLR4 ligands and not present on tolerogenic
DCs
In vivo, different functional DC phenotypes can be distinguished.
Tolerogenic DCs maintain tolerance by deleting self-reactive
T cells and generating regulatory T cells, whereas immunogenic
DCs induce immunity by activating effector and memory T cells
[23]. The migratory properties of DC subsets also vary, as
pretreatment of DCs with tolerogenic stimuli results in a reduced
capacity to migrate upon exposure to LPS and a loss of the ability
to reach draining lymph nodes [24]. In previous experiments we
clearly observed enhanced polySia expression on DCs triggered
for 2 days with LPS. To establish the conditions that allow the
highest polySia upregulation, we investigated next to immuno-
genic DC the potential of tolerogenic DCs to express polySia. The
expression levels of ST8Sia IV, as well as the cell surface
expression of polySia expression, was evaluated on different in vitro
cultured DCs. DCs matured with LPS for 2 days were used as a
model for immunogenic DCs and as a model for tolerogenic DCs,
DCs generated in the presence of dexamethasone or 1,25(dihy-
droxi-) vitamin D3 [25;26] were used. Surprisingly, only
immunogenic DCs but not tolerogenic DCs expressed high levels
of ST8Sia IV transcripts (Figure 3A). Similar to the expression of
ST8Sia IV, polySia is only expressed on the cell surface of
immunogenic and not on tolerogenic DCs (Figure 3B).
Next, we studied whether other TLR antagonists similarly
enhance polySia expression as the TLR4 ligand LPS. DCs were
treated with MyD88 dependent-TLR7/8 ligand R848 as well as
MyD88-independent/TRIF-dependent TLR3 ligand Poly I:C
[27]. We also investigated polySia expression of DCs matured
with LPS in combination with PGE2, since the presence of PGE2
during DC maturation has been described to control the
migratory capacity [28]. Although LPS induced the strongest
upregulation of ST8Sia IV (Figure 3C) and polySia expression on
the DC surface (Figure 3D), Poly I:C and R848 also enhanced
expression although clearly to a lower extent. The combination of
PGE2 and LPS did not further increase the LPS-mediated
upregulation of ST8Sia IV and polySia expression, indicating
that LPS is the crucial factor associated with polySia upregulation
on DCs.
The receptor of CCL21 on DCs is CCR7 [14]. CCR7 is
induced upon DC maturation whereas the expression of other
chemokine receptors is downregulated during DC maturation
[29;30]. When we analysed the regulation of CCR7 expression, we
detected similar kinetics to that of polySia, showing the highest
expression after 2 days maturation with LPS. However, in contrast
to the induction of polySia expression, all TLR-ligands tested
promoted equally high CCR7 expression levels (Figure 3E). Our
data indicate that TLR4 agonists provide the requirements for
optimal polySia and CCR7 expression on DCs that allow efficient
CCL21-induced migration of DCs. Furthermore, our data
demonstrate that TLR4 maturation of tolerogenic DCs upregu-
lates CCR7 but not polySia, indicating that probably tolerogenic
Figure 3. Polysialic acid and CCR7 expression levels on different DC subsets. (A) Expression levels of ST8Sia IV (N = 3) and (B) polySia
expression of immunogenic mDCs and dexamethasone or vitamin D3 tolerogenic mDCs, as measured by RT-PCR and flow cytometry respectively.
One representative donor out of three is shown. (C) ST8Sia IV expression levels in time of DCs matured with different TLR ligands as measured by RT-
PCR. (D) PolySia expression levels in time on DCs matured with different TLR ligands as measured by flow cytometry with mAb 735. One
representative donor is shown. (E) CCR7 expression levels in time on DCs matured with different TLR ligands were measured by flow cytometry. One
representative donor is shown. For all experiments the relative antibody binding compared to the secondary antibody control is depicted.
doi:10.1371/journal.pone.0006987.g003
PolySia Regulates DC Migration
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DCs are less capable of capturing CCL21 and may thus need
higher concentration gradients of CCL21 in order to perform
CCR7-mediated migration.
APCs expressing polySia are present in human tissue
To investigate if polySia-expressing cells are present in human
tissue, lymph node and skin biopsies were stained with anti-polySia
and anti-HLA-DR monoclonal antibodies. In the lymph node,
polySia-expressing cells could be identified in the T cell zone but
not in the B cell area (Figure 4A). These polySia-expressing cells in
the T cell zone of the lymph node were APCs, expressing HLA-
DR (Figure 4B). In skin, polySia-expressing APCs were located
only in the dermis (Figure 4C). Potentially, the polySia-expressing
APCs in the deep dermis may traffic during inflammation in a
CCL21-directed manner to the lymph node, where also polySia-
expressing HLA-DR+ cells could be found, followed by presenta-
tion of their antigen to T cells [14].
Based on the results of this study, the expression of polySia as a
marker for optimal migratory mDCs should be considered.
Especially in vaccination based therapies in which efficient
migration of ex vivo generated DCs is required, it should be taken
into account to analyse next to CCR7 the polySia expression levels
on the DCs. In conclusion, we demonstrate that the expression of
polySia on the cell surface of fully mature DCs following TLR4
triggering for 2 days captures CCL21 to optimally direct DC
migration towards the lymph nodes.
Material and Methods
Ethics statement
The study was approved by the VU university medical center
(VUmc) Amsterdam and the Commissie Wetenschappelijk
Onderzoek (CWO) by written consent. A written informed
consent was obtained from the healthy donors for the use of
samples.
Dendritic cell culture
Monocytes were isolated from healthy donors (Sanquin)
through Ficoll gradient centrifugation and positive selection of
CD14+ cells using MACS sorting (Miltenyi Biotec). Isolated
monocytes were cultured in RPMI 1640 (PAA laboratories)
containing 10% FCS (BioWhittaker), IL-4 (500 U/ml; Biosource)
and GM-CSF (800 U/ml; Biosource) for 7 days. Tolerogenic DC
were generated in the presence of dexamathasone (1026 M,
Figure 4. PolySia+ antigen presenting cells are present in human tissue. (A) Tissue biopsies of human lymph node were stained with moAb
735 (red). PolySia positive cells in the lymph node are located in the T cell area (T) but not in the B cell follicle (B). Nuclei are visualized in blue (106).
(B) Human lymph node was double stained using moAb 735 (red) and anti-HLA-DR (green). Arrows indicate double positive cells. Nuclei are visualized
in blue (206). (C) Tissue biopsies of human skin were double stained with moAb 735 (red) and anti-HLA-DR (green). Only deep in the dermis (D) and
not in the epidermis (E) polySia+ cells can be detected. Arrows indicate double positive cells. Nuclei are visualized in blue (206).
doi:10.1371/journal.pone.0006987.g004
PolySia Regulates DC Migration
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Sigma-Aldrich) or calcitriol (1,25(OH)2,D3, 10
28 M, Sigma-
Aldrich). At day 5 or day 6 maturation was induced by the
addition of 10 ng/ml LPS (E. Coli; Sigma-Aldrich) for 24 or
48 hours.
Sialidase treatment
Endo-N (AbCys) was used to specifically cleave off polySia. Cells
were pre-treated with the enzyme (0.7 U/ml) in medium
overnight and again 4 hours prior to the experiment. In order
to cleave off a2,3-, a2,6- and a2,8-linked sialic acids, cells were
pre-incubated with the Vibrio cholera neuraminidase (Roche,
2.561022 U/ml) for 1 hour at 37uC.
Real-Time PCR
Cells were lysed and mRNA was isolated using an mRNA
Capture kit (Roche). cDNA was synthesized using the Reverse
Transcription System kit (Promega) following manufacture’s
guidelines. Oligonucleotides were designed using the Primer
Express 2.0 software (Applied Biosystems) and synthesized by
Invitrogen Life Technologies (Invitrogen). Real-Time PCR
analysis was performed as previously described with the SYBR
Green method in an ABI 7900HT sequence detection system
(Applied Biosystems), using GAPDH as endogenous reference.
Flow cytometry
DCs (56104/well) were incubated with 10 mg/ml antibody 735
(kindly provided by Dr. Mu¨hlenhoff) or anti-CCR7 (BD) for 45
min. at RT in PBS with 1% BSA (Fluka Biochemika). Cells were
counter stained with a secondary FITC-labeled goat anti-mouse
IgG (Zymed) for 30 min. at RT in PBS with 1% BSA and analyzed
by flow cytometry (FACS Calibur, BD). Lectin stainings with
ConA (Concanavalin A, Sigma-Aldrich) and HPA (Helix pomatia
agglutinin, Sigma-Aldrich) were performed in TSM (20 mM Tris
(pH 7.4), 150 mM NaCl, 1 mM CaCl2, and 2 mM MgCl2). Alexa
488-labeled streptavidin was used to detect lectin binding.
O- and N-linked glycan modification
DC cultures were supplemented with 2 mg/ml of the mannosi-
dase I inhibitor Kifunensine (Kitasatosporia kifunensine; Calbiochem)
for at least 5 days to induce high mannose type glycosylation of
N-linked glycoproteins. O-glycosylation was abrogated by the
addition of 2 mM/ml Benzyl-a-GalNac (Sigma-Aldrich) for at
least 5 days.
Binding assay
Nunc maxisorp 96-wells ELISA plates (Nalge Nunc Interna-
tional) were coated overnight at 4uC with 10 mg/ml galactose,
a2,3-linked sialic acid, a2,6-linked sialic acid or a2,8-linked di-,
tri- or polySia coupled to biotinylated Polyacrylamide (Lectinity).
Wells were blocked for 30 min. at 37uC with TSM (20 mM Tris-
HCl, 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2) containing 1%
BSA (Fluka Biochemika). After washing 0.1 mg/ml CCL21
(Peprotech) in TSM with 1% BSA was added for 2 hours at
RT. For blocking studies, 0.1 mg/ml CCL21 was pre-incubated
with 25 mg/ml galactose or a2,8-linked polysialic acid coupled to
biotinylated Polyacrylamide (Lectinity) for 45 min. at 37uC in
TSM. CCL21 binding was determined by incubating 5 mg/ml
anti-CCL21 (R&D) in TSM with 1% BSA for 2 hours at RT,
followed by a detection step containing 10 mg/ml peroxidated
goat-anti-mouse antibody. The reaction was developed and optical
density was measured at 450 nm.
Chemotaxis assay
26105 cells in 100 ml RPMI 1640 (PAA laboratories) containing
10% FCS (BioWhittaker) were added to the upper well of a
Transwell (8.0 mm pores, Costar). Transwells were placed in a 24-
well plate with 600 ml full medium containing 100 ng/ml CCL21
(PeproTech) and incubated for 4 hours at 37uC in 5% CO2.
Migrated DC were collected from the bottom well and counted
using flow cytometry (BD). For blocking studies, both the lower
well containing CCL21 (100 ng/ml) and the upper well containing
the DCs were pre-treated with 10 mg/ml galactose or a2,8-linked
polysialic acid coupled to Polyacrylamide (Lectinity) for 45 min. at
37uC before performing the migration assay.
Immunohistochemistry
Human tissue sections (7 mm) were fixed in acetone and blocked
with goat serum prior to staining. Antibody 735 or rat anti-human
HLA-DR (Santa Cruz Biotechnology) were added at 10 mg/ml in
PBS containing 1% BSA (Fluka Biochemika) for 60 min. at 37uC.
Sections were counter stained using secondary isotype specific-
Alexa antibodies for 30 min. at room temperature, and analysed
by fluorescence microscopy (Leica microsystems).
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